参考文献

[1] Cox AD, etal., Drugging the undruggable RAS: missionpossible? Nat Rev Drug Discov 2014 ; 13 : 828 – 51

[2] Pylayeva-Gupta Y, etal., Rasoncogenes: weaving a tumo rigenic web. Nat Rev Cancer 2011; 11: 761–74.

[3] Liu Pingyu, etal. Targeting the untargetable KRAS in cancer therapy. ActaPharmaceutica Sinica B (2019).

[4] Ferrer I., etal. KRAS -Mutant non-small cell lungcancer: From biology to therapy. Lung Cancer, 2018, 24, 53–64.

[5] Nature. 2013 November 28; 503(7477): 548–551.

[6] Ruess DA, etal., Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Nat Med 2018; 24(7): 954-960.

[7] Ahmed, T. A., et al. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsetsof ERK-Dependent Tumors. Cell Reports, 2019,26(1), 65–78.

[8] Fedele C, etal., SHP2 Inhibition Prevents Adaptive Resistance to MEK inhibitors in Multiple Cancer Models. Cancer Discov 2018, pii: CD-18-0444.

[9] J. M.Ostrem, etal., Nature 2013; 503(7477): 548–551.

[10] M.P. Patricelli, etal., Cancer Discovery 2016; 6(3); 316–29.

[11] M.R. Janes etal., Cell 2018, 172(3); 578-589.

[12]https://www.amgen.com/media/news-releases/2019/09/amgen-announces-new-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-in-larger-patient-group-at-wclc-2019.

[13] Kessler, D., etal. Drugging an undruggable pocket on KRAS. Proceedings of theNational Academy of Sciences, 201904529.